Arbutus Biopharma Q1 revenue surges on Moderna settlement

Overview

• US infectious disease drugmaker's Q1 revenue surged on license revenue from Moderna litigation settlement

• Company posted net income of $169.7 mln, reversing a loss in the prior-year quarter

Outlook

• Arbutus expects to receive $178.7 mln from the Moderna settlement in July 2026

• Company says FDA Fast Track designation for imdusiran may expedite development and review

Result Drivers

• LITIGATION SETTLEMENT - Q1 revenue surge driven by license revenue from Genevant related to Moderna settlement

• COST REDUCTIONS - Lower research and development expenses due to workforce reduction and discontinuation of in-house research

• LEGAL FEES - Higher general and administrative expenses driven by legal fees related to Moderna settlement, partly offset by cost-cutting

Company press release: ID:nGNX26HPpf

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Arbutus Biopharma Corp is $5.00, about 16% above its May 12 closing price of $4.31

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.